Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.23
PODD's Cash to Debt is ranked higher than
67% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. PODD: 1.23 )
PODD' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.23

Equity to Asset 0.43
PODD's Equity to Asset is ranked higher than
55% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. PODD: 0.43 )
PODD' s 10-Year Equity to Asset Range
Min: -3.94   Max: 0.71
Current: 0.43

-3.94
0.71
F-Score: 7
Z-Score: 6.68
M-Score: -3.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -11.79
PODD's Operating margin (%) is ranked higher than
57% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. PODD: -11.79 )
PODD' s 10-Year Operating margin (%) Range
Min: -43010   Max: -11.79
Current: -11.79

-43010
-11.79
Net-margin (%) -18.20
PODD's Net-margin (%) is ranked higher than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. PODD: -18.20 )
PODD' s 10-Year Net-margin (%) Range
Min: -43272   Max: -18.2
Current: -18.2

-43272
-18.2
ROE (%) -36.10
PODD's ROE (%) is ranked higher than
53% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. PODD: -36.10 )
PODD' s 10-Year ROE (%) Range
Min: -337.19   Max: -36.1
Current: -36.1

-337.19
-36.1
ROA (%) -15.62
PODD's ROA (%) is ranked higher than
56% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. PODD: -15.62 )
PODD' s 10-Year ROA (%) Range
Min: -240.84   Max: -15.62
Current: -15.62

-240.84
-15.62
ROC (Joel Greenblatt) (%) -70.91
PODD's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. PODD: -70.91 )
PODD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -508   Max: -70.91
Current: -70.91

-508
-70.91
Revenue Growth (%) 23.10
PODD's Revenue Growth (%) is ranked higher than
93% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. PODD: 23.10 )
PODD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 101.6
Current: 23.1

0
101.6
EBITDA Growth (%) -29.80
PODD's EBITDA Growth (%) is ranked higher than
51% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. PODD: -29.80 )
PODD' s 10-Year EBITDA Growth (%) Range
Min: -72.6   Max: 25.9
Current: -29.8

-72.6
25.9
EPS Growth (%) -18.60
PODD's EPS Growth (%) is ranked higher than
59% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. PODD: -18.60 )
PODD' s 10-Year EPS Growth (%) Range
Min: -71   Max: 31.2
Current: -18.6

-71
31.2
» PODD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PODD Guru Trades in Q1 2013

Jim Simons 103,100 sh (New)
Tom Russo 209 sh (New)
PRIMECAP Management 1,865,956 sh (+29.51%)
Pioneer Investments 814,240 sh (+14.67%)
Mariko Gordon 598,860 sh (unchged)
Ron Baron 1,287,000 sh (unchged)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 1,105,770 sh (-7.01%)
» More
Q2 2013

PODD Guru Trades in Q2 2013

Mariko Gordon 1,637,047 sh (+173.36%)
Jim Simons 201,600 sh (+95.54%)
Ron Baron 1,287,000 sh (unchged)
PRIMECAP Management 1,865,956 sh (unchged)
Tom Russo Sold Out
Manning & Napier Advisors, Inc 707,270 sh (-36.04%)
Pioneer Investments 224,198 sh (-72.47%)
» More
Q3 2013

PODD Guru Trades in Q3 2013

PRIMECAP Management 1,865,956 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ron Baron 1,281,000 sh (-0.47%)
Jim Simons 192,500 sh (-4.51%)
Mariko Gordon 1,538,966 sh (-5.99%)
Pioneer Investments 204,527 sh (-8.77%)
» More
Q4 2013

PODD Guru Trades in Q4 2013

Steven Cohen 622,777 sh (New)
Mariko Gordon 1,662,694 sh (+8.04%)
PRIMECAP Management 1,865,956 sh (unchged)
Jim Simons 186,500 sh (-3.12%)
Ron Baron 650,000 sh (-49.26%)
Pioneer Investments 31,798 sh (-84.45%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2013-12-31 Add 8.04%0.19%$34.7 - $39.86 $ 43.5218%1662694
Ron Baron 2013-12-31 Reduce -49.26%0.1%$34.7 - $39.86 $ 43.5218%650000
Mariko Gordon 2013-09-30 Reduce -5.99%0.15%$30.64 - $37.75 $ 43.5230%1538966
Mariko Gordon 2013-06-30 Add 173.36%1.59%$24.57 - $31.69 $ 43.5254%1637047
PRIMECAP Management 2013-03-31 Add 29.51%0.02%$21.02 - $25.86 $ 43.5289%1865956
Ron Baron 2012-03-31 Add 29.4%0.03%$18.16 - $20.98 $ 43.52137%1063800
PRIMECAP Management 2012-03-31 Add 70.67%0.01%$18.16 - $20.98 $ 43.52137%972800
Ron Baron 2011-12-31 New Buy0.1%$14.29 - $18.98 $ 43.52156%822100
George Soros 2011-12-31 Sold Out 0.03%$14.29 - $18.98 $ 43.52156%0
PRIMECAP Management 2011-12-31 New Buy0.02%$14.29 - $18.98 $ 43.52156%570000
George Soros 2011-06-30 New Buy0.04%$18.3 - $21.86 $ 43.52113%126100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.30
PODD's P/B is ranked lower than
78% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. PODD: 19.30 )
PODD' s 10-Year P/B Range
Min: 3.13   Max: 1235
Current: 19.3

3.13
1235
P/S 9.50
PODD's P/S is ranked lower than
81% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. PODD: 9.50 )
PODD' s 10-Year P/S Range
Min: 1.25   Max: 25.53
Current: 9.5

1.25
25.53
EV-to-EBIT 1.60
PODD's EV-to-EBIT is ranked higher than
98% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. PODD: 1.60 )
PODD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 150.10
PODD's Price/Net Current Asset Value is ranked lower than
93% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. PODD: 150.10 )
PODD' s 10-Year Price/Net Current Asset Value Range
Min: 9.74   Max: 127.93
Current: 150.1

9.74
127.93
Price/Tangible Book 34.30
PODD's Price/Tangible Book is ranked lower than
93% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. PODD: 34.30 )
PODD' s 10-Year Price/Tangible Book Range
Min: 6.73   Max: 55.38
Current: 34.3

6.73
55.38
Price/Median PS Value 1.60
PODD's Price/Median PS Value is ranked lower than
59% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. PODD: 1.60 )
PODD' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 1.36
Current: 1.6

0.8
1.36
Forward Rate of Return (Yacktman) -39.65
PODD's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. PODD: -39.65 )
PODD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7   Max: -0.5
Current: -39.65

-7
-0.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:GOV.Germany
Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes. The Company's proprietary OmniPod Insulin Management System, which consists of its OmniPod disposable insulin infusion device and its handheld, wireless Personal Diabetes Manager, is the onlnt solution which provides significant lifestyle and other benefits and to expand the use of CSII therapy. The Company's marketing strategy is to build awareness for the benefits of the OmniPod System through a range of education programs, patient demonstration programs, support materials, media advertisey commercially-available insulin infusion system of its kind. The OmniPod System features only two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provide for virtually pain-free automated cannula insertion, communicate wirelessly and integrate a blood glucose meter. The OmniPod Insulin Management System was specifically designed to provide people with insulin-dependent diabetes with a diabetes managemements and events at the national, regional and local levels. It has registered the trademarks OMNIPOD and the OMNIPOD design with the United States Patent and Trademark Office on the Main Register. The OmniPod System competes with a number of existing insulin delivery devices as well as other methods for the treatment of diabetes. The OmniPod System mainly competes with Medtronic MiniMed, Animas Corporation, Deltec and Roche Diagnostics. The OmniPod System is a medical device subject to extensive and ongoing regulation by the U.S. Food and Drug Administration, or FDA, and other regulatory bodies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide